Atara Biotherapeutics to Present Phase 1 Study Update of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced the upcoming full release of new translational data and two-year open-label extension (OLE) clinical data from the study of ATA188 in progressive multiple sclerosis (MS). The findings will be presented as an ePoster at the 37th Congress of the...

Click to view original post